(Moncton, NB) September 2, 2021 – The future of breath screening for disease detection is one step closer to reality. Picomole, a Moncton-based medical technology company now has its Breath Sampler, ‘SohnoXB’, listed as a Class 1 device with the Food and Drug Administration (FDA) and has received a Health Canada (HC)Medical Device Establishment Licence (MDEL). The achievement of these milestones creates the opportunity for Picomole to provide SohnoXB to researchers across the US and Canada who are engaged in or exploring breath research.
“We are thrilled to see SohnoXB pass these important milestones. This is something we have worked very hard to achieve. Our team is excited about the potential opportunities for the research community and patient care in the coming years,” said Picomole CEO Dr. Stephen Graham.
Picomole technology has een used to identify lung cancer biomarkers in breath and recently is being used in studies to identify breast cancer and COVID-19 biomarkers in breath. In 2020, New Brunswick researchers published their lung cancer study results demonstrating an accuracy of Picomole’s platform technology to differentiate between Non-Small Cell Lung Cancer (NSCLC) and control cases of 86.1% (89.6% sensitivity and 80.7% specificity).
Picomole would like to thank the numerous research and funding partners for their ongoing support of breath research and technology development. With the support of our partners, one day, detecting disease will be as easy as breathing in and out.
-30-
